The Warsaw-based maker of orthopedic implants has filed suit to stop a Detroit-area law firm from making allegedly false claims and using its trademarks on websites designed to attract plaintiffs to sue Zimmer over one of its knee-replacement implants called NexGen.
Health reform will make health insurance a less-profitable business, but WellPoint Inc. got a vote of confidence from bond analysts because health-reform rules have turned out milder than expected and WellPoint’s financial performance has been particularly strong as the economy recovers.
The founder of Bloomington-based life sciences giant Cook Group Inc. and the wealthiest man in Indiana leaves a legacy of dozens of historic structures saved from decay or demolition. He also was a major donor to Indiana University and its athletics department.
Premiums for private health insurers in China are expected to rise to $90 billion by 2020 from $9 billion now, and WellPoint Inc. is angling for a big piece of that pie.
China remains a small market for Eli Lilly and Co. It generated $320 million in sales for the company in 2010, just 1.3 percent of its $23 billion in sales worldwide. But Lilly has big ambitions in China and is racing to capitalize on its rapid economic growth.
With economic growth in the United States sluggish, Indiana companies are joining the race to capitalize on the fast-growing Chinese economy—even as hundreds of millions of Chinese move into the middle class and adopt a Western-style thirst for goods and services.
Indiana University Health has canceled its plans for a $73 million administrative office building at 16th Street and Capitol Avenue and has instead purchased the Gateway Plaza tower at 10th and Illinois streets.
It was a good but not great year financially for three of the four largest hospital systems operating in the Indianapolis area last year—and hospital analysts are expecting several head winds to continue.
One year after President Obama signed the health reform overhaul, health insurers are buying less-regulated companies in a bid to offset the lower profits and growth they expect the law to cause.
In the face of new health reform restrictions, expect more small employers to opt for self-funded health benefits, concludes a report this week from Indianapolis-based United Benefit Advisors.
Drugmakers Merck & Co. and Sanofi-Aventis SA have abandoned plans to combine their animal-health businesses after wrestling with regulators for a year over potential divestitures.
Indianapolis-based Eli Lilly and Co. was among a list of possible suitors for about $1 billion in assets the two companies considered selling.
Marcadia execs French, Hawryluk reflect on massive growth of Carmel firm after sale to Roche.
Indiana wants to use its public health savings account program for low-income adults to cover people who will become newly eligible for Medicaid under the federal health care law beginning in 2014.
The Food and Drug Administration said Lilly needs to create a training program to ensure brain scans are interpreted properly.
Purdue University officials and others connected with the life sciences in Indiana say the planned $164 million Life and Health Sciences Quadrangle at the West Lafayette campus will mean high-paying jobs, retention of highly skilled scientists, and researchers who might well have left the state for either coast.
Eli Lilly and Co., Lilly Corporate Center, Indianapolis, 46285 (www.lilly.com) discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
Eli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated by a U.S. trade agency with the power to block imports of the copycat drug.
Unusual home on south side has a dozen bedrooms for folks who need to give up their own homes.
Indiana University Health is the latest system to drill employees ranging from clerks to physicians in how to treat patients.
Eli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly will be just fine after it has sustained the damage of the next three years.
